胃食道逆流症（GERD）の世界市場レポート 2024年

胃食道逆流症（GERD）市場規模は近年わずかながら成長しています。2023年の51億5,000万米ドルから2024年には52億5,000万米ドルに、CAGR2.0％で成長します。実績期間の成長は、ライフスタイルや食生活の変化、肥満の流行、胃酸過多治療に対する意識の高まり、製薬業界の世界化、胃酸過多治療への投資などに起因すると考えられます。

アルコール消費の高い発生率は、今後胃食道逆流症（GERD）市場の成長を促進すると予想されます。アルコール消費とは、エタノールを含む飲料を飲む行為を指します。アルコールの使用は、食道運動を低下させ、圧力レベルを低下させることにより、GERDの発症に寄与します。例えば、米国の政府機関National Institute on Alcohol Abuse and Alcoholismによると、2021年、米国におけるアルコール飲料からのエタノールの一人当たりの消費量は2.51ガロンに達し、2020年の2.44ガロンから2.9％増加しました。したがって、アルコール消費量の増加が胃食道逆流症（GERD）市場の拡大を後押ししています。

2023年の胃食道逆流症（GERD）市場で最大の地域は北米です。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。胃食道逆流症（GERD）レポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の胃食道逆流症（GERD）市場、薬剤タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 制酸薬
• プロトンポンプ阻害剤
• H2受容体ブロッカー
• プロキネティックエージェント
• ドーパミン受容体拮抗薬
• エンドシンチ
• ストレッタ
• エソフィクス
• 経口非切開噴門形成（TIF）
• 世界の胃食道逆流症（GERD）市場、施術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 侵襲的
• 低侵襲
• 世界の胃食道逆流症（GERD）市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 在宅ケア
• 専門クリニック

第7章 地域および国の分析

• 世界の胃食道逆流症（GERD）市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の胃食道逆流症（GERD）市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 胃食道逆流症（GERD）市場の競合情勢
• 胃食道逆流症（GERD）市場企業プロファイル
  • Pfizer Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Abbott Laboratories
  • GlaxoSmithKline Plc

第31章 その他の主要および革新的な企業

• Medtronic Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Reckitt Benckiser Group Plc
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Bausch Health Companies Inc.
• Johnson & Johnson MedTech
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company PLC
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Gastroesophageal Reflux Disease (GERD) Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal reflux disease (gerd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal reflux disease (gerd)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The gastroesophageal reflux disease (gerd) market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Type: Antacids; Proton Pump Inhibitors; H2 Receptor Blocker; Pro Kinetic Agents; Dopamine Receptor Antagonist; EndoCinch; Stretta; EsophyX; Transoral Incisionless Fundoplication (TIF)
• 2) By Procedure: Invasive; Minimally Invasive
• 3) By End-Users: Hospital; Homecare; Specialty Clinics
• Companies Mentioned: GlaxoSmithKline PLC; SRS Life Sciences; Johnson & Johnson Services Inc.; Takeda Pharmaceutical Company Limited; AstraZeneca Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Gastroesophageal reflux disease (GERD) is a condition characterized by the regurgitation of stomach acid into the esophagus, leading to irritation and discomfort. Treating GERD involves employing a range of medical strategies and interventions to effectively manage its symptoms and associated complications.

The primary drug categories used in the treatment of gastroesophageal reflux disease include antacids, proton pump inhibitors, H2 receptor blockers, prokinetic agents, dopamine receptor antagonists, and minimally invasive procedures such as EndoCinch, Stretta, Asphyx, and Transoral Incisionless Fundoplication (TIF). Antacids, for instance, function by neutralizing stomach acid, thus increasing the stomach's pH level to alleviate symptoms. Additionally, these treatment approaches can be divided into invasive and minimally invasive procedures, offering options that cater to the unique needs of patients. These therapies are made available through various healthcare providers, including hospitals, homecare services, and specialty clinics.

The gastroesophageal reflux disease (GERD) market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease (GERD) market statistics, including gastroesophageal reflux disease (GERD) industry global market size, regional shares, competitors with a gastroesophageal reflux disease (GERD) market share, detailed gastroesophageal reflux disease (GERD) market segments, market trends and opportunities and any further data you may need to thrive in the gastroesophageal reflux disease (GERD) industry. This gastroesophageal reflux disease (GERD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease (gerd) market size has grown marginally in recent years. It will grow from $5.15 billion in 2023 to $5.25 billion in 2024 at a compound annual growth rate (CAGR) of 2.0%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.

The gastroesophageal reflux disease (gerd) market size is expected to see steady growth in the next few years. It will grow to $5.74 billion in 2028 at a compound annual growth rate (CAGR) of 2.3%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services .

High treatment costs serve as a deterrent to the growth of the proliferative diabetic retinopathy (PDR) market during the projected period. The expenses associated with diagnosing and treating PDR can pose a significant financial burden, often reaching prohibitive levels. This encompasses the costs related to frequent eye examinations, laser therapy, and, in certain cases, surgical interventions. These elevated treatment expenses create financial challenges for both patients and healthcare systems. For instance, in 2023, as reported by Medical News Today, individuals typically face annual management costs ranging from $600 to $1,000 for the treatment of diabetic eye disease, while the cost of a vitrectomy procedure falls within the range of $8,000 to $14,000. As a result, the high treatment costs emerge as a constraining factor, impeding the growth of the proliferative diabetic retinopathy (PDR) market.

A high incidence of alcohol consumption is expected to propel the growth of the gastroesophageal reflux disease (GERD) market going forward. Alcohol consumption refers to the act of drinking a beverage containing ethanol, which is the only type of alcohol that is safe for human consumption. Alcohol use contributes to the development of GERD by decreasing esophageal motility and lowering pressure levels. For instance, according to the National Institute on Alcohol Abuse and Alcoholism, a US-based government agency, in 2021, the per capita consumption of ethanol from all alcoholic beverages in the United States reached 2.51 gallons, marking a 2.9% rise from 2.44 gallons in 2020. Hence, the elevated prevalence of alcohol consumption is propelling the expansion of the gastroesophageal reflux disease (GERD) market.

The decline in drug development for gastroesophageal reflux disease (GERD) poses a significant challenge and may potentially restrict the market's growth in the foreseeable future. This decline is primarily attributed to the transformation of numerous proton pump inhibitors (PPIs) into generic and over-the-counter formulations. As a result, the availability of innovative therapeutic options for GERD patients has dwindled, particularly for those who do not achieve desirable outcomes with existing treatments. For instance, a study published in November 2021 in Frontiers in Medicine, a reputable peer-reviewed journal, underscored the persistent unmet needs within GERD management. These unmet needs encompass rapid postprandial heartburn control, enhanced relief from volume reflux and acid regurgitation, effective nighttime heartburn relief, improved acid control in patients with Barrett's esophagus, and the flexibility in proton pump inhibitor (PPI) administration schedules. The diminishing focus on drug development is predominantly linked to the majority of PPIs transitioning into generic formulations. This trend, in turn, hampers the growth of the gastroesophageal reflux disease (GERD) market.

Prominent companies operating in the gastroesophageal reflux disease (GERD) market are dedicated to the introduction of innovative treatment devices for GERD, aimed at maintaining their market leadership. For example, in April 2023, Laborie Medical Technologies, a US-based medical technology firm, unveiled the alpHaONE wireless pH-capsule reflux testing diagnostic system, designed specifically for the diagnosis of gastroesophageal reflux disease (GERD). This advanced system is capable of providing up to 96 hours of comprehensive monitoring data. Notably, it boasts a compact and user-friendly design with conveniently enlarged buttons and a dependable capsule delivery system. Moreover, it features a dedicated software application equipped with a virtual instruction program and the option for users to customize symptom buttons, thereby enhancing the overall user experience. This innovative approach is significantly impacting the evolution of the GERD treatment market.

In October 2022, Sebela Pharmaceuticals Inc., a US-based pharmaceutical company specializing in the production of gastroesophageal reflux disease medications, established a strategic partnership with HK Inno.N Corporation, a South Korea-based pharmaceutical company, in an arrangement involving an undisclosed sum. This collaboration is aimed at jointly developing and launching tegoprazan, a pioneering potassium-competitive acid blocker (P-CAB), within the US and Canada. Tegoprazan, already authorized and available in South Korea and China, holds significant promise as an innovative addition to Sebela Pharmaceuticals' gastroenterology product line, catering to individuals dealing with gastroesophageal reflux disease.

Major players in the gastroesophageal reflux disease (gerd) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.

North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastroesophageal reflux disease (GERD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) market consists of revenues earned by entities by providing pharmaceutical therapies, surgical procedures and diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastroesophageal reflux disease (GERD) market also includes sales of gamma-aminobutyric acid type B receptor agonists and alginate antacids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Gastroesophageal Reflux Disease (GERD) Market Characteristics

3. Gastroesophageal Reflux Disease (GERD) Market Trends And Strategies

4. Gastroesophageal Reflux Disease (GERD) Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Gastroesophageal Reflux Disease (GERD) Market Size and Growth

• 5.1. Global Gastroesophageal Reflux Disease (GERD) Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Gastroesophageal Reflux Disease (GERD) Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Gastroesophageal Reflux Disease (GERD) Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gastroesophageal Reflux Disease (GERD) Market Segmentation

• 6.1. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Antacids
• Proton Pump Inhibitors
• H2 Receptor Blocker
• Pro Kinetic Agents
• Dopamine Receptor Antagonist
• EndoCinch
• Stretta
• EsophyX
• Transoral Incisionless Fundoplication (TIF)
• 6.2. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Invasive
• Minimally Invasive
• 6.3. Global Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital
• Homecare
• Specialty Clinics

7. Gastroesophageal Reflux Disease (GERD) Market Regional And Country Analysis

• 7.1. Global Gastroesophageal Reflux Disease (GERD) Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Gastroesophageal Reflux Disease (GERD) Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market

• 8.1. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gastroesophageal Reflux Disease (GERD) Market

• 9.1. China Gastroesophageal Reflux Disease (GERD) Market Overview
• 9.2. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gastroesophageal Reflux Disease (GERD) Market

• 10.1. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gastroesophageal Reflux Disease (GERD) Market

• 11.1. Japan Gastroesophageal Reflux Disease (GERD) Market Overview
• 11.2. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gastroesophageal Reflux Disease (GERD) Market

• 12.1. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gastroesophageal Reflux Disease (GERD) Market

• 13.1. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gastroesophageal Reflux Disease (GERD) Market

• 14.1. South Korea Gastroesophageal Reflux Disease (GERD) Market Overview
• 14.2. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gastroesophageal Reflux Disease (GERD) Market

• 15.1. Western Europe Gastroesophageal Reflux Disease (GERD) Market Overview
• 15.2. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gastroesophageal Reflux Disease (GERD) Market

• 16.1. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gastroesophageal Reflux Disease (GERD) Market

• 17.1. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gastroesophageal Reflux Disease (GERD) Market

• 18.1. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gastroesophageal Reflux Disease (GERD) Market

• 19.1. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gastroesophageal Reflux Disease (GERD) Market

• 20.1. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market

• 21.1. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market Overview
• 21.2. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gastroesophageal Reflux Disease (GERD) Market

• 22.1. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gastroesophageal Reflux Disease (GERD) Market

• 23.1. North America Gastroesophageal Reflux Disease (GERD) Market Overview
• 23.2. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gastroesophageal Reflux Disease (GERD) Market

• 24.1. USA Gastroesophageal Reflux Disease (GERD) Market Overview
• 24.2. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gastroesophageal Reflux Disease (GERD) Market

• 25.1. Canada Gastroesophageal Reflux Disease (GERD) Market Overview
• 25.2. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gastroesophageal Reflux Disease (GERD) Market

• 26.1. South America Gastroesophageal Reflux Disease (GERD) Market Overview
• 26.2. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gastroesophageal Reflux Disease (GERD) Market

• 27.1. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gastroesophageal Reflux Disease (GERD) Market

• 28.1. Middle East Gastroesophageal Reflux Disease (GERD) Market Overview
• 28.2. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gastroesophageal Reflux Disease (GERD) Market

• 29.1. Africa Gastroesophageal Reflux Disease (GERD) Market Overview
• 29.2. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By Procedure, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Gastroesophageal Reflux Disease (GERD) Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape And Company Profiles

• 30.1. Gastroesophageal Reflux Disease (GERD) Market Competitive Landscape
• 30.2. Gastroesophageal Reflux Disease (GERD) Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck and Co. Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Novartis AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Abbott Laboratories
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. GlaxoSmithKline Plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Gastroesophageal Reflux Disease (GERD) Market Other Major And Innovative Companies

• 31.1. Medtronic Plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Eli Lilly and Company
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Reckitt Benckiser Group Plc
• 31.7. Teva Pharmaceutical Industries Ltd.
• 31.8. Mylan N.V.
• 31.9. Bausch Health Companies Inc.
• 31.10. Johnson & Johnson MedTech
• 31.11. Eisai Co. Ltd.
• 31.12. Sun Pharmaceutical Industries Ltd.
• 31.13. Perrigo Company PLC
• 31.14. Dr. Reddy's Laboratories Ltd.
• 31.15. Aurobindo Pharma Limited

32. Global Gastroesophageal Reflux Disease (GERD) Market Competitive Benchmarking

33. Global Gastroesophageal Reflux Disease (GERD) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease (GERD) Market

35. Gastroesophageal Reflux Disease (GERD) Market Future Outlook and Potential Analysis

• 35.1 Gastroesophageal Reflux Disease (GERD) Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Gastroesophageal Reflux Disease (GERD) Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Gastroesophageal Reflux Disease (GERD) Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer